A Double Blind, Randomized Study to Compare Influence of Niacin/Laropiprant on Functional and Morphological Characteristics of Arterial Wall and Parameters of Inflammation in Subjects With Coronary Heart Disease Already Treated With a Statin.
Phase of Trial: Phase IV
Latest Information Update: 01 May 2014
At a glance
- Drugs Niacin/laropiprant (Primary)
- Indications Coronary disorders
- Focus Pharmacodynamics
- 07 Nov 2011 Actual initiation date (21 Apr 2010) added as reported by European Clinical Trials Database record.
- 05 Oct 2011 Actual end date (October 2011) added as reported by ClinicalTrials.gov.
- 05 Oct 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.